A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
Kyowa Kirin Co., Ltd.
Kyowa Kirin Co., Ltd.
St. Jude Children's Research Hospital
UNC Lineberger Comprehensive Cancer Center
OncoNano Medicine, Inc.
Treeline Biosciences, Inc.
SciTech Development, Inc.
Ohio State University Comprehensive Cancer Center
Novartis
City of Hope Medical Center
National Cancer Institute (NCI)
Daiichi Sankyo
Pfizer
Eisai Inc.
TopAlliance Biosciences
Rutgers, The State University of New Jersey
Seagen Inc.
Fate Therapeutics
Sierra Oncology LLC - a GSK company
Genzada Pharmaceuticals USA, Inc.
Repertoire Immune Medicines
National Institutes of Health Clinical Center (CC)
Jonsson Comprehensive Cancer Center
University of California, San Francisco
Celgene
Memorial Sloan Kettering Cancer Center
Tocagen Inc.
Acrotech Biopharma Inc.
University of Wisconsin, Madison
University of Wisconsin, Madison
Northwestern University
Mayo Clinic
Swiss Cancer Institute
Case Comprehensive Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
M.D. Anderson Cancer Center
Lytix Biopharma AS
Celgene
Celgene
Celgene
University of California, San Francisco
Massachusetts General Hospital
Mirna Therapeutics, Inc.
National Institutes of Health Clinical Center (CC)
Alliance for Clinical Trials in Oncology
Progen Pharmaceuticals
Bayer
Case Comprehensive Cancer Center
The Cleveland Clinic
City of Hope Medical Center
National Cancer Institute (NCI)